Eylea
PreclinicalSmall molecule
BayerEylea is used to treat eye diseases that cause vision loss, particularly age-related macular degeneration and diabetic retinopathy, by reducing abnormal blood vessel growth in the eye.[1] Eylea is currently being investigated across 2 indications[3], with its most advanced program in Preclinical.[1]
Eylea is one of 31 small molecule programs targeting Wet Age-Related Macular Degeneration. It is currently in Preclinical.
2
Indications
28
Total Trials
3
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
32 competitors in Diabetic Retinopathy
#DrugCompanyPhaseTrials
1Precose
BayerApproved
Avapro
SanofiApproved
Farxiga
AstraZenecaApproved
Tricor
JJagotec
Approved
EGRIFTA WR
TTheratechnologies
Approved
Xalatan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Glucophage
EMD SeronoApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lodosyn
LLaTonya J. Hickson
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Age-Related Macular Degeneration7 trials
Show 4 more trials
Diabetic Macular Edema4 trials
Show 1 more trial
Wet Age-Related Macular Degeneration3 trials
11 more indications
Efficacy1 trial
Effectiveness1 trial
Diabetic Macular Oedema1 trial
Efficacy and Safety1 trial
Quality of Life1 trial
Retinopathy of Prematurity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Eylea. EMBL-EBI & Wellcome Sanger Institute.
- [4]